JOURNAL OF CLINICAL ONCOLOGY

Amivantamab Plus Lazertinib in Atypical -Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
Tomasini P, Wang Y, Li Y, Felip E, Wu L, Cui J, Besse B, Spira AI, Neal JW, Goto K, Baik CS, Marmarelis ME, Ichihara E, Zhang Y, Lee JS, Lee SH, Yang JC, Michels S, Anastasiou Z, Curtin JC, Lyu X, Mahoney J, Demirdjian L, Meyer CS, Zhang Y, Leconte I, Lorenzini P, Knoblauch RE, Trani L, Baig M, Bauml JM, Cho BC and
For patients with advanced non-small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor () mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited.
Erratum: Quizartinib for Newly Diagnosed -Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study
Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, López-López JA, Vives S, López-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, Gómez-Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ, Paiva B, Boluda B, Casas-Avilés I, Lloret P, Sánchez MJ, Rodríguez-Medina C, Cuevas L, Raposo-Puglia JÁ, Mateos MC, Olivares M, Martínez-Chamorro C, Alonso N, Suárez S, Sánchez-Vadillo I, Rodríguez MS, González BJ, Martínez-Francés A, Cuello R, Fernández A, Martínez-Cuadrón D, Labrador J and
Cost Utility of Geriatric Assessment and Management in Older Adults With Cancer: From Evidence to Implementation
Taher A, Ring A and Battisti NML
Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials
Sherry AD, Ludmir EB and Msaouel P
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Harter P, Marmé F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, Ray-Coquard I, Garcia-Duran C, Jonuskiene G, Heitz F, Béllier C, Pérez-Fidalgo JA, El-Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges A, Fabbro M, Hasenburg A, Fehm T, Schmalfeldt B and Pautier P
To evaluate atezolizumab combined with bevacizumab and non-platinum-based chemotherapy for recurrent ovarian cancer.
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4
Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Szabados B, Peyton CC, Pradere B, Ku JH, Shore N, Bögemann M, Preston MA, Xylinas E, Sanchez de Llano C, Gong C, Hasan M, Urtishak K, Battaglia S, Stitou H, Bhanvadia S, Sweiti H and Psutka SP
Standard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant cisplatin-based chemotherapy (NAC). However, many patients are ineligible for or refuse cisplatin. SunRISe-4 (NCT04919512) is an open-label, multicenter, parallel-cohort phase II study assessing neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy in patients with MIBC.
Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN
Nichetti F, Procaccio L, Lonardi S and Bergamo F
Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?
Guo K, Lu J, Zhou X and Zheng S
Reply to: Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials
Ferris RL, Bauman JE, Wang H and Zandberg DP
FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies
Akdogan O, Sutcuoglu O, Tuzcu TU, Yazici O and Ozdemir N
Reply to: "FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies," "Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?," and "Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN"
Ducreux M, Texier M and Bouche O
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C and Levin VA
STELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma.
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquières H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janíková A, Mocikova H, Fürst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F and Cerhan JR
Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed.
Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer
Ratain MJ and Fojo AT
Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?
Yadav RK and Miller KD
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Lee Batlevi C, Tilly H and Flowers CR
Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
Cliff ERS, Lew TE, Simon F, Hilal T, Anderson MA, Thompson PA and Seymour JF
If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not
Schmitz KH and Ligibel JA
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
Sharman JP, Liu B, Wang DY, Leow CC and Barr PM
Are You Bereaved?
Paul TK
Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial
Li JJ, Zhang WJ, Zeng XH, Zhang QY, Chen L, Wu J, Liu GY, Wang ZH, Hu XB, Hu YY, Li ZL and Shao ZM
To evaluate the efficacy and safety of the bispecific human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) TQB2102 in the neoadjuvant treatment of HER2-positive breast cancer.